Body mass index and serum markers associated with progression-free survival in lung cancer patients treated with immune checkpoint inhibitors

Table 1 Characteristic of patients in this study (N = 66)

Characteristic	Total N (%)	BMI (kg/m2)			ALB (g/dL)			Creatinine (μmol/L)			LMR			PLR
Characteristic	Total N (%)	< 25 (n = 44, 66.7%)	≥ 25 (n = 22, 33.3%)	P	< 37 (n = 13, 19.7%)	≥ 37 (n = 53, 80.3%)	P	< 61.8 (n = 37, 56.1%)	≥ 61.8 (n = 29, 43.9%)	P	< 2.12 (n = 12, 18.2%)	≥ 2.12 (n = 54, 81.8%)	P	< 135 (n = 22, 33.3%)	≥ 135 (n = 44, 66.7%)	P
Age (years)
≥65	23 (34.8%)	15	8	0.855	7	16	0.109	12	11	0.642	4	19	0.903	6	17	0.361
<65	43 (65.2%)	29	14		6	37		25	18		8	35		16	27
Sex
Female	19 (28.8%)	12	7	0.701	3	16	0.612	14	5	0.067	3	16	0.749	6	13	0.848
Male	47 (71.2%)	32	15		10	37		23	24		9	38		16	31
Treatment line
First line	29 (43.9%)	20	9	0.726	6	23	0.858	14	15	0.259	6	23	0.64	7	22	0.161
Second or higher	37 (56.1%)	24	13		7	30		23	14		6	31		15	22
Histology
Non-small cell l	51 (77.3%)	33	18	0.533	12	39	0.149	29	22	0.809	10	41	0.58	21	30	0.013
Small cell	15 (22.7%)	11	4		1	14		8	7		2	13		1	14
ICIs
Anti-PD-1 agent	52 (78.8%)	33	19	0.287	11	41	0.566	30	22	0.607	10	42	0.67	20	32	0.089
Anti-PD-L1 agent	14 (21.2%)	11	3		2	12		7	7		2	12		2	12

ICIs Immune checkpoint inhibitors, BMI body mass index, ALB serum albumin, LMR lymphocyte-to-monocyte ratio, PLR platelet-to-lymphocyte ratio
P values in bold indicate statistically significant differences (P < 0.05)

ISSN: 1471-2407